Indian biotech major Biocon Ltd on Monday said the US Food and Drug Administration (FDA) had audited its aseptic drug product facility here and issued an establishment inspection report on its current good manufacturing practice.
"The FDA had audited our drug making facility between May 25-June 3 and classified its outcome as a voluntary action indicated," said the city-based company in a statement here.
The report also stated that the regulator's inspection was closed.
The nearly four decades drug and research firm makes genetic active pharmaceutical ingredients for domestic and overseas markets, worldwide.
The regulatory clearance has helped the company's blue-chip scrip of Rs 5 face value gain Rs 21.85 (5.54 per cent) per share on the BSE to trade at Rs 416.20 per share in the post-noon session as against last Friday's closing price of Rs 394.35 and opening rate of Rs 408.
--IANS
fb/ksk/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
